These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 33765338)

  • 41.
    Hill MA; Alexander WB; Guo B; Kato Y; Patra K; O'Dell MR; McCall MN; Whitney-Miller CL; Bardeesy N; Hezel AF
    Cancer Res; 2018 Aug; 78(16):4445-4451. PubMed ID: 29871934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
    Nepal C; O'Rourke CJ; Oliveira DVNP; Taranta A; Shema S; Gautam P; Calderaro J; Barbour A; Raggi C; Wennerberg K; Wang XW; Lautem A; Roberts LR; Andersen JB
    Hepatology; 2018 Sep; 68(3):949-963. PubMed ID: 29278425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
    Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
    Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
    Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
    Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
    Buckarma E; De La Cruz G; Truty M; Nagorney D; Cleary S; Kendrick M; Borad M; Graham RP; Gores G; Smoot R
    HPB (Oxford); 2022 Oct; 24(10):1748-1756. PubMed ID: 35718679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
    Goeppert B; Folseraas T; Roessler S; Kloor M; Volckmar AL; Endris V; Buchhalter I; Stenzinger A; Grzyb K; Grimsrud MM; Gornicka B; von Seth E; Reynolds GM; Franke A; Gotthardt DN; Mehrabi A; Cheung A; Verheij J; Arola J; Mäkisalo H; Eide TJ; Weidemann S; Cheville JC; Mazza G; Hirschfield GM; Ponsioen CY; Bergquist A; Milkiewicz P; Lazaridis KN; Schramm C; Manns MP; Färkkilä M; Vogel A; ; Boberg KM; Schirmacher P; Karlsen TH
    Hepatology; 2020 Oct; 72(4):1253-1266. PubMed ID: 31925805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
    Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
    Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
    Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R
    Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
    Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
    Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PARP-1 selectively impairs
    Keggenhoff FL; Castven D; Becker D; Stojkovic S; Castven J; Zimpel C; Straub BK; Gerber T; Langer H; Hähnel P; Kindler T; Fahrer J; O'Rourke CJ; Ehmer U; Saborowski A; Ma L; Wang XW; Gaiser T; Matter MS; Sina C; Derer S; Lee JS; Roessler S; Kaina B; Andersen JB; Galle PR; Marquardt JU
    Gut; 2024 Sep; 73(10):1712-1724. PubMed ID: 38857989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
    Li F; Peiris MN; Donoghue DJ
    Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutational landscape of intrahepatic cholangiocarcinoma.
    Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
    Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.